Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL)

Bhawna Sirohi; David Cunningham; Andy Norman; Kim Last; Ian Chau; Alan Horwich; Jacqui Oates; Geoffrey Chong; Andrew Wotherspoon

doi:10.1080/10245330701214095

Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL)

Hematology. 2007 Apr;12(2):149-53. doi: 10.1080/10245330701214095.

Authors

Bhawna Sirohi¹, David Cunningham, Andy Norman, Kim Last, Ian Chau, Alan Horwich, Jacqui Oates, Geoffrey Chong, Andrew Wotherspoon

Affiliation

¹ Lymphoma Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

PMID: 17454196
DOI: 10.1080/10245330701214095

Abstract

This is the first report of the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) with Rituximab (GEM-PR) for diffuse large B-cell lymphoma (DLBCL). Thirty-nine patients with relapsed or refractory DLBCL in this study received GEM-P with (n = 24) or without Rituximab (n = 15) 64% patients had Stage III/IV disease. The overall response rate (ORR) was 59% (95% CI 42.1-74.4); 11/39 (28%) patients attained complete response. Patients received a median of two cycles (1-4) of treatment. For GEM-PR group, the ORR was 67% (95% CI 45-84%) compared to 47% (95% CI 21-73%) in GEM-P alone. one-year progression-free survival was 51% (95% CI 28-69%) in GEM-PR group compared to 27% (95% CI 8-49%) in GEM-P alone (P = 0.04). GEM-P is an effective second-line regimen in patients with relapsed or refractory DLBCL and the addition of Rituximab appears to further improve outcomes.

MeSH terms

Adolescent
Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cisplatin / administration & dosage
Cisplatin / adverse effects
Combined Modality Therapy
Deoxycytidine / administration & dosage
Deoxycytidine / adverse effects
Deoxycytidine / analogs & derivatives
Disease-Free Survival
Drug Evaluation
Female
Gemcitabine
Humans
Immunotherapy*
Kaplan-Meier Estimate
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / radiotherapy
Lymphoma, Large B-Cell, Diffuse / surgery
Lymphoma, Large B-Cell, Diffuse / therapy*
Male
Methylprednisolone / administration & dosage
Methylprednisolone / adverse effects
Middle Aged
Peripheral Blood Stem Cell Transplantation
Radiotherapy, Adjuvant
Remission Induction
Retrospective Studies
Rituximab
Salvage Therapy*
Survival Analysis
Survival Rate
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Deoxycytidine
Rituximab
Cisplatin
Methylprednisolone
Gemcitabine